Press Release | ERDERA Clinical Trial Call

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA has opened its Clinical Trial Call 2026, a funding opportunity for multinational early-phase interventional clinical trials in rare diseases.

The call supports sponsor-led Phase I, Phase I/II and Phase II trials of medicinal products designed to generate robust clinical evidence, strengthen regulatory readiness and improve trial feasibility across countries.

Up to €30 million is dedicated to the call, with individual project budgets broadly expected in the range of €1 million to €5 million.

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Source

ERDERA

Author

ERDERA

You might also be interested in

Genetic Mapping

New clinical trial guidance supports research beyond the hospital

New international guidance supports decentralised clinical trials, pragmatic designs and the use of real-world data.
State of the art rare disease country reports ERDERA 2025

State of the art 2025 rare disease country report: Cyprus

This 2025 country report outlines the policy, research, care and support landscape for rare diseases in Cyprus.
ERDERA Knowledge Exchange Meeting

ERDERA Knowledge Exchange Meeting on Drug Repurposing for Rare Diseases

November 25 - November 26
Discover practical pathways to repurpose medicines for rare diseases, exchange experiences and best practices between underrepresented and high-performing countries, and build new partnerships at the ERDERA Knowledge Exchange Meeting in Riga on 25-26 November.
ERDERA - World Orphan Drug Congress - JVDPhotography-40

Can AI deliver for rare diseases? ERDERA brings the debate to WODC Europe

ERDERA will return to the World Orphan Drug Congress Europe with a booth and an interactive pre-conference workshop examining where artificial intelligence can support rare disease research and therapeutic development, and where human expertise remains essential.

ERDERA Search